Bruno Dumas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bruno Dumas has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Claude Gaillardin
AgroParisTech, UMR INRA 1319 Micalis
1 shared publication Corinne Brocard‐Masson
Sanofi‐Aventis, Process Development Biotechnology, Industrial Affairs, Vitry sur Seine, France
1 shared publicationKarine Assemat‐Lebrun
Sanofi‐Aventis, Process Development Biotechnology, Industrial Affairs, Vitry sur Seine, France
1 shared publication- Monique Bolotin-Fukuhara
Laboratoire de Genetique Moleculaire, Institute de Genetique et Microbiologie, Batiment 400, Université Paris‐Sud, 91405 Orsay cedex, France
1 shared publication Tilman Achstetter
Industrial Microbiology, University of Applied Sciences, Bremen, Germany
1 shared publication
Latest Publications
- Open Access
- 5 November 2010
- Published by Oxford University Press (OUP) in FEMS Yeast Research
- Vol. 10 (8) , 959-960
Yeasts as a model for human diseases
- 5 November 2010
- Published by Oxford University Press (OUP) in FEMS Yeast Research
- Vol. 10 (8) , 959-960
Open AccessYeasts as a model for human diseases
- 17 March 2006
- Published by Wiley in Biotechnology Journal
- Vol. 1 (3) , 299-307
Hydrocortisone made in yeast: Metabolic engineering turns a unicellular microorganism into a drug‐synthesizing factory
Inspired by the successful work of converting Saccharomyces cerevisiae into an microorganism capable of synthesizing hydrocortisone, a 27‐carbon molecule, from ethanol, a 2‐carbon molecule, this review provides an overview of the potential of yeast as a recombinant organism in the 21st century. Yeast has been used by man for more than 6000 years, and is still paving the way to new discoveries. It was the first eukaryotic organism to be sequenced, in 1996, and the first to produce hydrocortisone in 2003. In addition, extensive genome–wide analyses have been performed with yeast. In this review, we discuss the pros and cons of using yeast to produce small therapeutic molecules. It is obvious that S. cerevisiae has a cutting edge advantage of being a well–known organism and time will tell if yeast “biohydrocortisone” is a unique example or the beginning of a long list of yeast bioproducts. Other organisms, such as plants and bacteria, are competing with yeast. Bacteria produce a wealth of marketed molecules and plants are capable of producing extremely complex molecules with an unbeatable yield. However, S. cerevisiae offers a unique mix of the simplicity of a recombinant organism combined with the complexity of a eukaryote.
- 17 March 2006
- Published by Wiley in Biotechnology Journal
- Vol. 1 (3) , 299-307
Hydrocortisone made in yeast: Metabolic engineering turns a unicellular microorganism into a drug‐synthesizing factory
Inspired by the successful work of converting Saccharomyces cerevisiae into an microorganism capable of synthesizing hydrocortisone, a 27‐carbon molecule, from ethanol, a 2‐carbon molecule, this review provides an overview of the potential of yeast as a recombinant organism in the 21st century. Yeast has been used by man for more than 6000 years, and is still paving the way to new discoveries. It was the first eukaryotic organism to be sequenced, in 1996, and the first to produce hydrocortisone in 2003. In addition, extensive genome–wide analyses have been performed with yeast. In this review, we discuss the pros and cons of using yeast to produce small therapeutic molecules. It is obvious that S. cerevisiae has a cutting edge advantage of being a well–known organism and time will tell if yeast “biohydrocortisone” is a unique example or the beginning of a long list of yeast bioproducts. Other organisms, such as plants and bacteria, are competing with yeast. Bacteria produce a wealth of marketed molecules and plants are capable of producing extremely complex molecules with an unbeatable yield. However, S. cerevisiae offers a unique mix of the simplicity of a recombinant organism combined with the complexity of a eukaryote.